The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Minimal Residual Disease Market Progress Between 2026 And 2030?
The minimal residual disease market size has experienced swift expansion in recent years. It is anticipated to increase from $2.01 billion in 2025 to $2.26 billion in 2026, driven by a compound annual growth rate (CAGR) of 12.5%. The historical growth can be credited to the rise in leukemia and lymphoma cases, increasing use of flow cytometry testing, early adoption of pcr-based mrd detection, growing clinical focus on relapse prediction, and the expansion of diagnostic laboratory capabilities.
The minimal residual disease market is projected to experience substantial expansion over the upcoming years, anticipating a valuation of $3.57 billion by 2030, with a compound annual growth rate (CAGR) of 12.2%. This growth during the forecast period is attributable to several factors, including the rapid expansion of NGS-based MRD testing, the escalating demand for tailored oncology treatments, the advancement of highly sensitive molecular assays, the broader integration of liquid biopsy MRD testing, and increased investment in research for cancer diagnostics. Key trends expected within this period encompass the embrace of precision medicine for MRD detection, the incorporation of AI to boost sensitivity in MRD testing, the broadening of cloud-based data management solutions for MRD monitoring, the implementation of IoT-enabled connectivity in MRD diagnostic platforms, and the increasing automation and digitalization within laboratory MRD analysis.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
Which Primary Drivers Are Impacting The Minimal Residual Disease Market Growth?
The rising incidence of cancer is anticipated to drive the expansion of the minimal residual disease market in the future. Cancer refers to a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This growing occurrence of cancer stems from various contributors, including an aging demographic, heightened exposure to environmental cancer-causing agents, detrimental lifestyle choices, and inherited susceptibilities. The escalating prevalence of cancer fuels the need for accurate MRD testing to identify remaining cancer cells, facilitating prompt intervention and tailored therapeutic approaches. Such testing improves the ability to predict relapse and leads to better patient results. As an illustration, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, forecast more than 35 million new cancer cases by 2050, signifying a 77% rise from the estimated 20 million cases in 2022. Consequently, the expanding incidence of cancer is a key factor propelling the minimal residual disease market’s development.
What Segment Categories Shape The Minimal Residual Disease Market Segment Landscape?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Which Trends Are Shaping Growth In The Minimal Residual Disease Market?
Leading companies active in the minimal residual disease (MRD) market are concentrating on developing advanced ultra-sensitive assays to improve early detection and patient management. These ultra-sensitive assays are laboratory tests designed to identify circulating tumor DNA at exceptionally low frequencies with high accuracy, facilitating earlier recognition of cancer recurrence and better-informed treatment decisions. For instance, in April 2025, Natera, Inc., a US-based provider of cell-free DNA and genetic testing, launched the Signatera Genome MRD test, which features a personalized, tumor-informed assay derived from a patient’s whole genome sequence and matched normal DNA. This test employs multiplex polymerase chain reaction and next-generation sequencing technology to detect tumor DNA at concentrations as low as 1 part per million and below for research use. It has undergone clinical validation across numerous cancer types, including breast, colorectal, non-small cell lung, melanoma, and renal cell carcinoma. Signatera Genome is capable of identifying postsurgical patients with an elevated risk of recurrence, provides predictive clinical utility, supports both clinical and research applications, and is covered by Medicare for a broad spectrum of indications, thereby enabling more precise and informed treatment strategies.
Who Are The Companies Operating Across The Minimal Residual Disease Market Value Chain?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina Inc., Personalis Inc., Asuragen Inc., ARUP Laboratories Inc., Myriad Genetics Inc., Luminex Corporation, EntroGen Inc., 3B BlackBio Biotech India, Bioartis, PerkinElmer Inc.
Get The Full Minimal Residual Disease Market Report:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
Which Region Represents The Largest Share Of The Minimal Residual Disease Market?
North America was the largest region in the minimal residual disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Minimal Residual Disease Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
Browse Through More Reports Similar to the Global Minimal Residual Disease Market 2026, By The Business Research Company
Mineral Oil Market Report 2026
https://www.thebusinessresearchcompany.com/report/mineral-oil-global-market-report
Mineral Supplements Market Report
https://www.thebusinessresearchcompany.com/report/mineral-supplements-global-market-report
Mineral Market Report
https://www.thebusinessresearchcompany.com/report/mineral-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model